Acesso livre
Acesso livre

Covid-19 (Temas de Saúde Pública)

Perspectiva | As evidências sobre a 4ª dose das vacinas contra Covid & a questão complicada dos limites de idade.

6 Abr, 2022 | 12:53h

The Evidence On 4th Doses of Covid Vaccines & the Thorny Question of Age Thresholds – Absolutely Maybe Blog, by Hilda Bastian

Conteúdos relacionados:

U.S. approves second Covid-19 booster for people 50 and older and immunocompromised individuals.

[Preprint] Retrospective cohort study: second booster vaccine and Covid-19 mortality in adults 60 to 100 years old.

Among health care workers, a fourth dose vaccine effectiveness against any SARS-CoV-2 Omicron variant infection was 30% for the Pfizer–BioNTech and 11% for the Moderna.

[Preprint] Fourth dose of COVID vaccine offers only slight boost against Omicron infection.

Covid-19: Fourth vaccine doses—who needs them and why?

[Not published yet] Study in Israel finds fourth COVID booster has limited efficacy.

 

Comentário no Twitter

 

Estudo de coorte | Mudança nas taxas de mortalidade por doença cardíaca e AVC antes e durante a pandemia de Covid-19.

6 Abr, 2022 | 12:46h

Age-Adjusted Mortality Rates and Age and Risk–Associated Contributions to Change in Heart Disease and Stroke Mortality, 2011-2019 and 2019-2020 – JAMA Network Open

Comentários:

Several-Fold Increase in Stroke and Heart Disease Deaths During COVID-19 Pandemic – NeurologyToday

2019 to 2020 Saw Risk-Linked Deaths From Heart Disease, Stroke Up – HealthDay

 

Comentário do autor no Twitter (fio – clique pra saber mais). Artigo e imagens sob CC-BY License

 

Estratégia da OMS para preparo, prontidão e plano de resposta para o fim da emergência global de Covid-19 em 2022.

5 Abr, 2022 | 12:30h

Strategic Preparedness, Readiness and Response Plan to End the Global COVID-19 Emergency in 2022 – World Health Organization

 

Comentário no Twitter (fio – clique para saber mais)

 

Dois novos estudos mostram que a vacinação forneceu proteção adicional após infecção por Covid-19.

5 Abr, 2022 | 12:14h

Estudo 1: Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden – The Lancet Infectious Diseases

Estudo 2: Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study – The Lancet Infectious Diseases

Comentários:

Interplay of infection and vaccination in long-term protection from COVID-19 – The Lancet Infectious Diseases

Effectiveness of SARS-CoV-2 vaccines in the post-natural infection world – The Lancet Infectious Diseases

Vaccines offer substantial extra protection after COVID-19 infection – CIDRAP

Had COVID? Getting Vaccine Boosts Resilience Even More, Studies Show – HealthDay

Conteúdos relacionados:

Retrospective cohort study: Pfizer vaccine reduces the risk of reinfection after recovery from Covid-19.

Cohort study: Protection against SARS-CoV-2 after Covid-19 vaccination lasts longer in patients with previous infection.

 

Comentário no Twitter fio – clique para saber)

 

Estratégia de vigilância genômica global da OMS para patógenos com potencial pandêmico e epidêmico 2022-2032.

1 Abr, 2022 | 12:36h

Global genomic surveillance strategy for pathogens with pandemic and epidemic potential 2022–2032 – World Health Organization

Comunicado de imprensa: WHO releases 10-year strategy for genomic surveillance of pathogens – World Health Organization

 

Comentário no Twitter (fio – clique para saber mais)

 

Estudo de caso-controle | Em crianças de 5 a 11 anos de idade, a vacina da Pfizer mostrou efetividade de 68% contra internação causada pela variante Ômicron.

1 Abr, 2022 | 12:29h

BNT162b2 Protection against the Omicron Variant in Children and Adolescents – New England Journal of Medicine

Comentário: COVID vaccination of children age 5-11 cut omicron hospitalizations by 68% – Children’s Hospital Boston

Conteúdo relacionado: [Preprint] Study shows significantly reduced effectiveness of the Pfizer vaccine in children 5 to 11 after the emergency of the Omicron variant.

 

Comentário no Twitter

 

Risco de reinfecções por SARS-CoV-2 em crianças: um estudo de vigilância nacional prospectiva na Inglaterra.

1 Abr, 2022 | 12:24h

Risk of SARS-CoV-2 reinfections in children: a prospective national surveillance study between January, 2020, and July, 2021, in England – The Lancet Child & Adolescent Health

Comentário convidado: Importance of understanding the reinfection risk of COVID-19 in children – The Lancet Child & Adolescent Health

 

Comentário no Twitter

 

[Preprint] Estudo de coorte retrospectiva | 2º reforço de vacina e mortalidade por Covid-19 em adultos de 60 a 100 anos de idade.

31 Mar, 2022 | 13:44h

Second Booster Vaccine and Covid-19 Mortality in Adults 60 to 100 Years Old – Research Square

Comentários:

Huge Study Finds Second COVID-19 Booster is ‘Life-saving’ for Over 60s – Health Policy Watch

Fourth COVID-19 vaccine dose substantially reduces mortality in the elderly – News Medical

EUA aprovam 2ª dose de reforço contra Covid-19 para pessoas de 50 anos de idade ou mais e indivíduos imunocomprometidos.

31 Mar, 2022 | 13:41h

U.S. approves second Covid-19 booster for people 50 and older – STAT

FDA OKs second COVID booster shot for older Americans – CIDRAP

Ver diretriz: Coronavirus (COVID-19) Update: FDA Authorizes Second Booster Dose of Two COVID-19 Vaccines for Older and Immunocompromised Individuals – U.S. Food & Drug Administration

Estudo RECOVERY – 2 anos.

31 Mar, 2022 | 13:38h

The RECOVERY Trial – two years on – University of Oxford

Conteúdos relacionados:

How the UK found the first effective Covid-19 treatment — and saved a million lives (about the RECOVERY trial and the effects of Dexamethasone)

Covid: The London bus trip that saved maybe a million lives (about the creation of the RECOVERY Trial)

Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19 – Recovery Trial

[Preprint] RECOVERY trial shows Baricitinib reduces deaths in patients hospitalized with COVID-19.

RCT: CPAP improved outcomes in patients with acute hypoxemic respiratory failure due to COVID-19, but high-flow nasal oxygen was not better than conventional oxygen therapy.

RECOVERY Trial: No benefit from convalescent plasma in patients admitted to hospital with COVID-19.

RECOVERY Trial: Aspirin as an add-on therapy did not reduce mortality in patients hospitalized with COVID-19.

RECOVERY trial: In hospitalized COVID-19 patients with hypoxia and systemic inflammation (C-reactive protein ≥75 mg/L), tocilizumab improved survival and other clinical outcomes

RECOVERY trial: Azithromycin not beneficial for patients admitted to hospital with COVID-19

[Preprint] RECOVERY trial finds Regeneron’s monoclonal antibody combination reduces deaths for hospitalized COVID-19 patients who have not mounted their own immune response.

RECOVERY trial: Effect of hydroxychloroquine in hospitalized patients with Covid-19

Randomized trial: Lopinavir–ritonavir not beneficial for patients admitted to hospital with COVID-19

 

Comentário no Twitter

 

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.